The FHOD3 gene accounts for 1-2% of hypertrophic cardiomyopathy cases and should be routinely included in genetic testing panels.
May support expanding HCM genetic panels to include FHOD3; leaves open validation before routine clinical adoption.
FHOD3 is a novel disease gene in hypertrophic cardiomyopathy, accounting for approximately 1% to 2% of cases. The phenotype and the rate of cardiovascular events are similar to those reported in unselected cohorts. The FHOD3 gene should be routinely included in hypertrophic cardiomyopathy genetic testing panels.
No takes yet. Share an insight, caveat, or question.
Ochoa et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: